Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 apceth, bluebird bio Enter Mfg. Tie-up | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

apceth, bluebird bio Enter Mfg. Tie-up

apceth to operate as the commercial manufacturer in Europe for Zynteglo, bluebird bio’s gene therapy for β-thalassemia

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

apceth Biopharma GmbH, a provider of cell and gene therapy manufacturing, will operate as the commercial manufacturer in Europe for Zynteglo, a product of bluebird bio. The European Commission (EC) has granted conditional marketing authorization for Zynteglo, a gene therapy for patients 12 years and older with transfusion-dependent β-thalassemia (TDT) who do not have a β0/β0 genotype, for whom haematopoietic stem cell (HSC) transplantation is appropriate but a human leukocyte antigen (HLA)-matched related HSC donor is not available.
 
“We are proud to be the commercial manufacturing partner of bluebird bio and to be part of bringing this life-changing therapy to TDT patients in Europe,” said Christine Guenther, chief executive officer, apceth Biopharma. “Being one of the very few companies worldwide to manufacture a cell-based gene therapy for commercial use marks a milestone for our company.”
 
apceth Biopharma is bluebird bio’s clinical and commercial manufacturing partner for Europe not only for Zynteglo, but also for bluebird bio’s product candidate Lenti-D for cerebral adrenoleukodystrophy. Following a successful long-term manufacturing relationship, apceth Biopharma and bluebird bio entered a commercial drug product manufacturing agreement in 2016.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics